ICOS and autoimmune disease: But the benefits of ICOS immunotherapy can be partly gained either by limiting ICOS+ Treg expansion and function in cancer diseases or by enhancing Treg immunoregulatory capacity in autoimmune diseases, although they could also be obtained by regulating effector T cells or Tfh cells, which depends on different drug mechanisms and context conditions.